Crossmark

De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1007/s10549-019-05265-1

Published Online: 2019-05-11

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Awan, Arif Ali

Hutton, Brian

Hilton, John

Mazzarello, Sasha

Van Poznak, Catherine

Vandermeer, Lisa

Bota, Brianne

Stober, Carol

Sienkiewicz, Marta

Fergusson, Dean

Shorr, Risa

Clemons, Mark https://orcid.org/0000-0002-0738-2713
License Information

Text and Data Mining valid from 2019-05-11
More Information

Article History

Received: 31 March 2019

Accepted: 29 April 2019

First Online: 11 May 2019

Compliance with ethical standards

:

: Dr. Awan reports participating in the Novartis Canada Advisory Board on the use of Ribociclib. Dr. Hutton reports personal fees from Cornerstone Research, outside the submitted work. Dr. van Poznak reports personal fees from UpToDate and institutional research funds from Bayer, outside the submitted work. The remaining authors declare that they have no conflicts of interest (Hilton, Mazzarello, Vandermeer, Bota, Stober, Sienkiewicz, Fergusson, Shorr, and Clemons).

: This article does not contain any studies with human participants performed by any of the authors.

: Not applicable as this is a systematic review.